PSMD4 and hepatocellular carcinoma: This study was able to identify several candidate biomarkers, such as KRT8, FN1, NQO1 and PSMD4 [39], and also suggesting treatment options such as cytarabine, cetuximab, AE788, and L19-IL2 (a monoclonal antibody-cytokine conjugate currently being used to treat other types of cancer) can be potential therapeutics for HCC.